drugset
drugset / Trial / NCT05265013

ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without Metastases

NCT05265013 ↗

Phase 2 Terminated 16 enrolled Rakuten Medical, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Phase 2 Single-arm Study of ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck, With or Without Metastases, Not Amenable to Curative Local Treatment

Timeline

Start
2022-04-19
Primary completion
2023-11-20
Completion
2024-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject CETUXIMAB SAROTALOCAN Other / unclassified 640 mg/m2 Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous

Indications

head and neck cancer